Taken together, these data cement NOTCH1 mutation status as critical biomarker for response to conventional therapy and offer high-resolution insight as to how NOTCH1 mutations alter T-ALL cell state. This evidence concerns the gene NOTCH1 and acute lymphoblastic leukemia.